恒瑞 1 类新药新适应症报上市，治疗血小板减少

新浪医药08-12

8 月 11 日，CDE 官网显示，恒瑞海曲泊帕乙醇胺片新适应症上市申请获受理。根据临床试验进展，业内推测用于肿瘤化疗所致血小板减少症（CIT）。来源：CDE 官网海曲泊帕乙醇胺片是恒瑞医药研发的 1 类创新药，也是中国首个自主研发的非肽类口服血小板生成素受体激动剂，通过激活 TPO-R 介导的 STAT 和 MAPK 信号转导通路，促进血小板生成。海曲泊帕乙醇胺片于 2021 年在中国获批上市并...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2558428516?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-12 19:29","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2558428516","market":"us","top_or_hot":-1,"title":"恒瑞 1 类新药新适应症报上市，治疗血小板减少","media":"新浪医药","content":"<div>\n<p>8 月 11 日，CDE 官网显示，恒瑞海曲泊帕乙醇胺片新适应症上市申请获受理。根据临床试验进展，业内推测用于肿瘤化疗所致血小板减少症（CIT）。来源：CDE 官网海曲泊帕乙醇胺片是恒瑞医药研发的 1 类创新药，也是中国首个自主研发的非肽类口服血小板生成素受体激动剂，通过激活 TPO-R 介导的 STAT 和 MAPK 信号转导通路，促进血小板生成。海曲泊帕乙醇胺片于 2021 年在中国获批上市并...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812194052a6e19d31&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞 1 类新药新适应症报上市，治疗血小板减少</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞 1 类新药新适应症报上市，治疗血小板减少\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-12 19:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812194052a6e19d31&s=b><strong>新浪医药</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8 月 11 日，CDE 官网显示，恒瑞海曲泊帕乙醇胺片新适应症上市申请获受理。根据临床试验进展，业内推测用于肿瘤化疗所致血小板减少症（CIT）。来源：CDE 官网海曲泊帕乙醇胺片是恒瑞医药研发的 1 类创新药，也是中国首个自主研发的非肽类口服血小板生成素受体激动剂，通过激活 TPO-R 介导的 STAT 和 MAPK 信号转导通路，促进血小板生成。海曲泊帕乙醇胺片于 2021 年在中国获批上市并...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812194052a6e19d31&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4199","symbol_name":"纸制品","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812194052a6e19d31&s=b","article_id":"2558428516","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812194052a6e19d31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2558428516","pubTimestamp":1754998162,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8 月 11 日，CDE 官网显示，恒瑞海曲泊帕乙醇胺片新适应症上市申请获受理。2022 年 6 月，海曲泊帕乙醇胺片用于恶性肿瘤化疗所致血小板减少症适应症获得美国 FDA 授予的孤儿药资格认定。2024 年 6 月，恒瑞在 2024 ESMO 大会上公布了海曲泊帕乙醇胺片治疗恶性肿瘤化疗所致血小板减少症的 III 期临床数据。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4199":"纸制品","SAA":"ProShares Ultra SmallCap600","ITP":"IT科技包装"},"translate_title":"Hengrui Class 1 new drug with new indications is reported on the market to treat thrombocytopenia","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAA":1,"ITP":1},"content_text":"8 月 11 日，CDE 官网显示，恒瑞海曲泊帕乙醇胺片新适应症上市申请获受理。根据临床试验进展，业内推测用于肿瘤化疗所致血小板减少症（CIT）。来源：CDE 官网海曲泊帕乙醇胺片是恒瑞医药研发的 1 类创新药，也是中国首个自主研发的非肽类口服血小板生成素受体激动剂，通过激活 TPO-R 介导的 STAT 和 MAPK 信号转导通路，促进血小板生成。海曲泊帕乙醇胺片于 2021 年在中国获批上市并纳入医保目录，适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症（ITP）成人患者；以及对免疫抑制治疗（IST）疗效不佳的重型再生障碍性贫血（SAA）成人患者，是中国首个获批 ITP 和 SAA 双适应症的TPO-RA。2022 年 6 月，海曲泊帕乙醇胺片用于恶性肿瘤化疗所致血小板减少症适应症获得美国 FDA 授予的孤儿药资格认定。2024 年 6 月，恒瑞在 2024 ESMO 大会上公布了海曲泊帕乙醇胺片治疗恶性肿瘤化疗所致血小板减少症的 III 期临床数据。结果显示，海曲泊帕乙醇胺片组的治疗应答者比例显著高于安慰剂组。除ITP、SAA、CIT 外，海曲泊帕乙醇胺片还在进一步探索拓展新适应症，包括初治重型再生障碍性贫血、儿童原发免疫性血小板减少症、有创性操作的慢性肝病伴血小板减少症、初治非重型再生障碍性贫血等。国内首个获批的小分子非肽类血小板生成素受体激动剂（TPO-RA）类药物，是诺华原研的艾曲泊帕乙醇胺片。其他获批的TPO-RA包括复星医药代理的阿伐曲泊帕片、盐野义原研的芦曲泊帕。新浪医药综合加入读者交流群：—精彩回顾—首个药糖尿病干细胞疗法上市在即中国，走出一个全球First in classmRNA 肿瘤疫苗，中国力量快速崛起医药巨头裁员，愈演愈烈又一巨头栽了，GSK 6.25亿项目折戟商  务  合  作  ：杨小雨 15210041717","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2558428516","isCrawlerRequest":true}